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Colorectal cancer incidence in Spain increased considerably between the early nineties and
2010. To reverse this tendency, screenings were progressively implemented starting the
year 2001, targeting the population aged 50 to 69 years.
Objectives
This study aimed to update colorectal cancer incidence and mortality trends in Spain and
provide a detailed analysis of disease management and risk factors involved in in-hospital
mortality.
Methods
To this aim, anonymised primary and specialised care admission records from 2011 to 2016
were extracted from a Spanish claims database representative of all Spanish regions.
Results
Primary care files from 37,317 patients and specialised care files from 192,048 patients
were obtained, in which males represented the 56.17% and 60.70% of patients respectively.
In-hospital mortality rate was 10.07% and remained stable during the study period, similarly
to colorectal cancer incidence within the hospitalised population, which was 106 per 10,000
patients. Patients deceased during the hospitalisation presented an increased presence of
metastatic tumours. Mean length of hospital stay decreased significantly over the study
period from 13.43 days to 11.67 days (p<0.001), similarly to patients’ 30-day readmission
rate, which registered a decrease from the 15.29% to 13.58% (p<0.001). In consequence,
the direct medical cost measured per patient, of €10,992, decreased over time. The imple-
mentation of colorectal cancer screening programmes caused a significant decrease in the
number of new diagnoses in patients aged 75 to 79 years that may be attributable to the
implementation of colorectal cancer screening programmes; however, in-hospital mortality
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was not reduced. Metastatic tumours and other conditions as anaemia are associated with
higher in-hospital mortality rates.
Introduction
Colorectal cancer is the third most common cancer type worldwide, with a global age-stan-
dardised incidence rate of 19.7 per 100,000 persons in 2018 [1]; in Europe, 30.0 cases per
100,000 were reached in 2018 [1].
The number of new colorectal cancer cases has increased over time in correlation with sev-
eral lifestyle and environmental factors such as smoking habits, alcohol consumption, diet
quality, obesity or physical activity [2]. In Spain, the age-standardised incidence rate of colon
cancer increased 12.63 points between 1993 and 2010 in males, 3.51 points rectal cancer,
whereas in females both rates increased 2.22 points and 1.79 points respectively [3]. In addi-
tion, malignant neoplasms of the colon and rectum were responsible for 9.2% of all cancer-
related deaths in 2018, only surpassed by lung cancer [4].
Given the increasing relevance of colorectal cancer, most European countries including
Spain are developing population screening programmes centred on a specific target popula-
tion, in accordance with the European guidelines for quality assurance in colorectal cancer
screening and diagnosis [5]. In Spain, colorectal cancer screenings were implemented the year
2001 in three regions and were progressively extended to the whole country [6]. Currently,
screenings target the population aged 50 to 69 years, and reached participation rates of 45.53%
in 2016 that follow an increasing tendency [7]. The positive outcome of such programmes has
been measured in several occasions; colorectal malignant neoplasms diagnosed via population
screening programme present more favourable histopathological features than those diag-
nosed based on symptoms [8]. Additionally, their positive impact has been measured as a
modest decrease in colorectal cancer mortality, especially in populations with a higher risk [9,
10]. On the other hand, the implementation of such programmes has led to measurable
decreases in colorectal cancer incidence in certain regions [11].
Previous evaluations of the Spanish population showed a growing incidence of colorectal
cancer in the country starting the year 1975 [12]; whereas a recent study focused on colorectal
cancer mortality revealed increased mortality rates among male patients [13]. These analyses
of the population at risk have directed the implementation of the aforementioned screening
programmes. However, a deeper understanding of the factors that influence colorectal cancer
risk in Spain will be relevant for the implementation of prevention programmes, while the
analysis of disease management and the aspects that determine disease prognosis can contrib-
ute to decrease mortality rates.
Thus, the objective of this study was to update disease incidence and mortality trends in
Spain after ten years of screenings, and to provide a description of disease management and
the factors that may play a role in colorectal cancer in-hospital mortality.
Methods
Study design and setting
A retrospective multicentre observational study was set to analyse primary and specialised care
(hospital and other specialised care centres) records of patients admitted with colorectal cancer
in Spain. Records were obtained from a claims database from the Spanish Ministry of Health
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that is representative of all Spanish regions. Data inclusion was set to comprise most recent
available data at the moment of the analysis, from 1 Jan 2011 to 31 Dec 2016.
Data extraction
The database, managed by the Spanish Ministry of Health, was codified at the healthcare cen-
tre level by means of the 9th revision of the International Statistical Classification of Diseases
and Related Health Problems, Clinical Modification (ICD-9-CM) until 2015 and the 10th revi-
sion (ICD-10-CM) after 2016. The International Classification of Primary Care second edition
(ICPC-2) was used to codify primary care records. Thus, the records of patients admitted with
colorectal cancer as admission motive in specialised care centres were petitioned using the cor-
responding ICD-9-CM and ICD-10-CM codes, whereas to obtain primary care records data
was selected via the appropriate ICPC-2 codes (Table 1).
Data extraction is conducted by the Spanish Ministry of Health that selects and provides
the files of interest. Only anonymised, de-identified data is obtained, in accordance with the
principles of Good Clinical Practice and the Declaration of Helsinki. This research did not
involve human participants and there was no access to identifying information; in this context
the Spanish legislation does not require patient consent and ethics committee approval [14].
Study variables
The database contains raw information registered on admission detailing the patient profile
and admission details. The primary care database registers patients’ sex, age, income level and
employment status, centre location (Spanish region), date of admission and admission motive.
The specialised care database registers patients’ sex and age, hospital location (Spanish region),
date of admission, type of admission, date of discharge, type of discharge (including death),
service that discharged the patient, length of stay, readmission rate, admission motive, second-
ary diagnoses registered during the admission, tumour morphology (codified with the Interna-
tional Classification of diseases for Oncology (ICD-O-3) codes), medical procedures
performed and cost of the admission.
Data analysis
In all cases, only the admissions with colorectal cancer listed as admission motive were ana-
lysed. The extraction of single-patient data for the characterisation of the patient population in
both primary and specialised care was based on the first admission per patient due to colorec-
tal cancer. Direct medical costs were calculated by using the standardised average expenses of
admissions and medical procedures determined by the Spanish Ministry of Health indicated
in the dataset. This calculation included all expenses related to specialised care admissions:
treatment (examination, medication and surgery), nutrition, costs associated to personnel,
medical equipment and resources corrected per groups of patients.
Table 1. Codes used for primary care and specialised care data extraction.
Code Definition Coding system Time period Setting
D75 Malignant neoplasm of colon and rectum ICPC-2 2011–2016 Primary care
153.0 to 153.9 Malignant neoplasm of colon ICD-9-CM 2011–2015 Specialised care
154.0 to 154.8 Malignant neoplasm of rectum rectosigmoid junction and anus ICD-9-CM 2011–2015 Specialised care
C18.0 to C18.9 Malignant neoplasm of colon ICD-10-CM 2016 Specialised care
C19 Malignant neoplasm of rectosigmoid junction ICD-10-CM 2016 Specialised care
https://doi.org/10.1371/journal.pone.0228795.t001
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Frequencies and percentages are presented for dichotomous variables and mean and stan-
dard deviation or error were calculated for quantitative variables. Incidence rate within the
hospitalised population was calculated as the proportion of patients admitted with colorectal
cancer as the admission motive within the specialised care database. The characteristics of
deceased patients were analysed for the admission in which death was registered. To assess the
association of secondary conditions with in-hospital mortality, odd ratios (OR) with 95% con-
fidence interval (CI) were used, with the group of patients non-deceased during the hospitali-
sation as the reference group. Two-tailed T-student or one-way analysis of variance were used
as appropriate and two-sample Z tests were used to test for differences in sample proportions,
with a p<0.05 considered statistically significant.
Data presentation is mainly descriptive. Statistical analyses were performed using Microsoft
Excel© Professional Plus 2010 (Microsoft Corporation, Redmond, WA, USA) and StataSE 12
for Windows (StataCorp LP. 2011. Stata Statistical Software: Release 12. College Station, TX,
USA).
Results
The ICPC-2 code corresponding to colorectal cancer was used to extract 99,653 primary care
admission records, corresponding to 37,317 single patients admitted with this cancer type
between 2011 and 2016. The 56.17% of these patients were males and 43.83% females. Special-
ised care files were extracted via the equivalent ICD-9-CM and ICD-10-CM codes. In total,
records of 230,361 admissions were obtained, corresponding to 192,048 single patients. Of
these, 60.70% were males, 64.76% when only rectum cancer was considered.
The number of single patients attended per year slightly increased over the study period,
with 31,531 attended in 2011 versus 33,181 attended in 2016, yet, the incidence of colorectal
cancer within the hospitalised population was stable between 2011 and 2015, averaging 106.39
per 10,000 patients. The year 2016 an incidence of 88.05 per 10,000 was estimated.
Patients’ age at the first registered admission per colorectal cancer was 70.40 years
(SD = 13.89) in primary care and 70.52 years (SD = 12.02) in specialised care. Overall, patients’
age distribution analysis showed a peak in the age range of 75 to 79 years, that was especially
noticeable the year 2011 (Fig 1). The year 2016 the portion of patients aged 75 to 79 years was
reduced 1.3 folds (p<0.001), compensated with small increases in younger patients (aged 55 to
69) and similar raises in patients aged 90 to 99.
The data registered in primary care centres included descriptive data of patients’ income
level and employment status. Patients with an income under €18,000 represented 69.12% of all
registries and 27.06% were between €18,000 and €99,000. Consistently with patients’ age,
67.09 of registered patients were pensioners, whereas 17.73% were active workers. Patients not
active or unemployed summed the 15.19%.
Hospitalisation and specialised care records allowed the analysis per tumour type. Seventy-
two per cent of cancers were malignant neoplasms of the colon and 27.88% were found in the
rectum, rectosigmoid junction or anus (Table 2).
In addition, the majority of specified malignant neoplasms of colon and rectum were ade-
nocarcinomas (86.00%), and 8.58% of the patients were diagnosed with a metastatic tumour
during the first hospitalisation. Interestingly, an in-hospital mortality rate of 10.07% was mea-
sured during the study period, with no significant trends observed over time or in the temporal
analysis stratified per patients’ age. Males and females showed similar mortality rates, 10.15%
vs. 9.96%. Mortality increased with patients’ age; in patients <71 years, the mortality rate was
7.10% while in patients >71 years it was 12.64% (p<0.001). In those older than 80 years of age
in-hospital mortality was 15.99% (p<0.001 vs. <80). Variation was also observed in an
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individual analysis per Spanish region; patients in Cantabria, Catalonia and La Rioja displayed
the lowest in-hospital mortality rates (7.59%, 7.99% and 8.81% respectively), whereas the high-
est were measured in Ceuta and Melilla and the Canary Islands (18.17% and 17.85%)
(Table 3).
Independently, secondary diagnoses registered upon admission were used to assess the
effect of comorbid conditions in colorectal cancer mortality. With all admissions considered,
metastatic malignant neoplasms, mainly of the liver, were found in virtually all patients
deceased during the hospitalisation (Table 4). The portion of metastatic neoplasms of the ret-
roperitoneum and the lung were also increased in this group, found in 16.81% and 20.55% of
all deceased patients respectively.
Fig 1. Patients’ age at first hospital admission per colorectal cancer the years 2011–2016.
https://doi.org/10.1371/journal.pone.0228795.g001
Table 2. Percentage and characteristics of patients diagnosed with malignant neoplasms of colon, rectum or neuroendocrine colorectal tumours.
Tumour classification Patients, % Males, % Age, mean (SD)
All patients (N = 192,048) - 60.70 70.52 (12.02)
Malignant neoplasm of colon (N = 138,514) 72.12 59.14 71.25 (11.92)
alignant neoplasm of rectum, rectosigmoid junction and anus (N = 53,534) 27.88 64.76 68.90 (12.04)
Patients with a specified neoplasm (N = 115,192) - 60,72 71.02 (12.00)
Adenocarcinoma (N = 99,159) 86.00 61.16 70.64 (11.80)
Metastatic carcinoma (N = 9,895) 8.58 56.62 73.52 (13.20)
Carcinoma, unspecified (N = 5,743) 4.98 59.55 73.16 (12.60)
Adenoma (N = 395) 0.34 68.61 71.63 (11.09)
https://doi.org/10.1371/journal.pone.0228795.t002
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The overall mean length of hospital stay (LOHS) decreased significantly over time from
13.43 days (SE = 0.07) in 2011 to 11.67 days (SE = 0.08) in 2016 (p<0.001), as it happened with
the readmission rate, which decreased from 15.29% to 13.58% (p<0.001). Altogether, 41.21%
of all the admissions included in the study were registered as non-scheduled or urgent, and
99.63% required inpatient care.
General and digestive surgery and other surgery services were responsible for patients’ dis-
charge in 70.50% of admissions, and patients’ destination after discharge was principally their
home. Patients deceased during hospitalisation were treated by internal medicine and oncol-
ogy services, in addition to palliative care units.
The hospital and specialised care database permits the calculation of hospitalisation costs,
which considers the estimated cost per all medical procedures performed, equipment and
Table 3. Analysis of patient profile and in-hospital mortality per Spanish region.
Spanish region N Age % malignant neoplasms of colon % malignant neoplasms of rectum % in-hospital mortality
Andalusia 29,273 70.72 66.65 33.35 12.49
Aragon 6,560 70.53 66.72 33.28 12.20
Principality of Asturias 6,142 70.77 66.93 33.07 12.55
Balearic Islands 3,058 70.18 65.34 34.66 10.53
Canary Islands 6,567 70.56 66.59 33.41 17.85
Cantabria 2,627 70.60 66.88 33.12 7.59
Castille and León 15,446 70.62 66.35 33.65 12.72
Castilla—La Mancha 8,220 70.46 66.80 33.20 12.38
Catalonia 34,822 70.60 67.16 32.84 7.99
Valencian Community 25,008 70.39 66.64 33.36 10.86
Extremadura 4,872 70.50 66.36 33.64 12.49
Galicia 16,162 70.68 67.08 32.92 11.50
Community of Madrid 23,930 70.67 66.79 33.21 10.28
Region of Murcia 5,124 70.61 66.41 33.59 10.20
Chartered Community of Navarre 3,421 70.41 66.09 33.91 12.52
Basque Autonomous Communty 11,465 70.47 66.25 33.75 12.42
La Rioja 1,462 70.59 65.25 34.75 8.81
Ceuta and Melilla 373 71.99 67.57 32.43 18.17
https://doi.org/10.1371/journal.pone.0228795.t003
Table 4. Secondary diagnoses in patients with colorectal cancer and in deceased patients.
Secondary diagnoses All patients, % Deceased patients, % Odds ratio, 95% CI
Metastatic malignant neoplasm 57.38 100.00 2.58 (2.53–2.63)
Liver 15.04 37.37 2.92 (2.84–3.00)
lymph nodes 10.43 8.85 0.82 (0.78–0.86)
Lung 6.38 20.55 4.20 (4.04–4.36)
retroperitoneum 6.00 16.81 3.44 (3.31–3.58)
Essential hypertension 33.29 28.32 0.82 (0.80–0.84)
Disorders of lipoid metabolism 18.74 12.82 0.65 (0.62–0.67)
Diabetes mellitus 16.79 15.80 0.92 (0.88–0.95)
Intestinal obstruction without mention of hernia 13.43 20.29 1.57 (1.52–1.63)
Anaemia 10.86 12.20 1.12 (1.07–1.16)
Cardiac dysrhythmias 8.72 13.60 1.63 (1.56–1.70)
Tobacco use disorder 7.47 6.60 0.86 (0.81–0.90)
Overweight and obesity 7.39 4.03 0.51 (0.48–0.54)
https://doi.org/10.1371/journal.pone.0228795.t004
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other factors such as patients’ condition. In order to provide a more detailed evaluation of
medical costs, the most relevant registered medical procedures were investigated (Table 5).
Various surgical resection and excision procedures were used, while the infusion of chemo-
therapy was registered in only 11.53% of all admissions.
Finally, taking the aforementioned factors into account, the direct medical cost measured
per admission averaged €10,992, with a decreasing tendency observed over time (p<0.001)
(Fig 2). The mean direct medical cost per patient in those with a tumour of the colon was
€10,464, whereas the mean cost per patient with a rectal tumour was €12,339. Clear tendencies
were not observed when analysing costs stratified per patients’ age. A decrease in the cost per
patient was observed the year 2016.
Discussion
The analysis of primary and specialised care files of patients diagnosed with colorectal cancer
in Spain revealed an increased number of new cases among males, mostly neoplasms of the
colon, which is comparable to data obtained in other countries [15]. In Spain, screening pro-
grammes have been progressively implemented starting the year 2001 with only three regions
and expanding, including individuals aged 50 to 69 years [5, 12]. The reduction observed in
this study in the number of patients aged 75 to 79 years between the years 2011 and 2016 could
be explained by the increased early detection of these tumours as a consequence of the imple-
mentation of such screening programmes. Incidence among the hospitalised population was
relatively elevated, with 106.39 per 10,000 patients between 2011 and 2015, and remained sta-
ble during the study period. Incidence decreased in 2016, presumably due to the introduction
of ICD-10 coding, indicating the need to interpret this data cautiously.
In addition, it is estimated that approximately 20% of the patients with colorectal cancer
present with metastasis at the time of diagnosis [16], a rate that was smaller in the present
study, with only the 8.58%, although the use of other ICD codes to codify these cases cannot be
discarded. The diagnosis of metastatic tumours among colorectal cancer patients during the
first admission remarks the importance of early detection, achieved via screening programmes
that should be promoted to achieve higher participation rates. Its utility has been proven
Table 5. Principal medical procedures performed in the course of the hospital admission.
Medical procedures % of admissions
Imaging 74.99
computerized axial tomography of abdomen 30.55
computerized axial tomography of thorax 11.64
routine chest x-ray 8.24
ultrasound of abdomen and retroperitoneum 7.67
Biopsies 17.79
closed [endoscopic] biopsy of large intestine 13.72
Chemotherapy 11.53
Surgery -
open and other right hemicolectomy 12.92
other anterior resection of rectum 10.37
other small-to-large intestinal anastomosis 9.06
open and other sigmoidectomy 8.00
Other -
transfusion of packed cells 10.89
injection of antibiotic 10.03
https://doi.org/10.1371/journal.pone.0228795.t005
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worldwide and in the country [17]; indeed, one study analysing key performance indicators of
the first screening years in Spain indicated that the majority of cancers were detected at an
early stage [18].
In addition, in-hospital mortality was seemingly elevated, with no significant trends
observed over time. Previous inpatient mortality estimations in Spain measured comparable
rates, between 10 and 11%, yet, measurements in other countries situated those rates under the
3% when only taking into account post-surgery mortality [13, 19, 20]. Data obtained herein
suggests that in-hospital mortality is not directly related to surgical procedures; instead, most
deceased patients were registered in oncology services or palliative care units. On the other
hand, the presence of certain comorbid conditions could play a role in in-hospital mortality.
Metastatic tumours were present in virtually all deceased patients; likewise, anaemia and intes-
tinal obstruction were increased in these patients. Anaemia is frequently observed in colorectal
cancer patients and preoperative anaemia has been associated with poor survival [21]. Herein
it appears to have an effect in disease course; nevertheless, its relation with preoperative indica-
tors has not been investigated. The influence of diet quality, obesity and physical activity in
tumour progression, is not apparent in this study, which could be a consequence of the weight
loss observed in the last stages of the disease [2, 22]. It must be taken into account that second-
ary conditions observed in deceased patients are registered during the hospitalisation process
in which the patient dies. This could explain the negative relation found between certain con-
ditions as essential hypertension, disorders of lipoid metabolism, overweight and obesity and
in-hospital mortality. As for diabetes, the modest protective effect found in this study is in con-
tradiction with previous meta-analyses, which suggested a negative effect of this condition on
colorectal cancer survival, and must be interpreted with caution [23].
Fig 2. Mean direct medical cost of specialised care per patient measured over time.
https://doi.org/10.1371/journal.pone.0228795.g002
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Regarding disease management, data in Spain showed a tendency to decrease hospitalisa-
tion times, which has been followed by a reduction in readmission rates. Such tendencies
could reflect the application of more efficient treatment and recovery protocols, and therapies
that take into account tumour histopathological characteristics [24, 25]; in addition, the intro-
duction of screening programmes may lead to earlier cancer detection, requiring less complex
treatments and with fewer complications [18]. Previous evaluations determined that patients
above 80 years of age receive similar treatment than younger patients, yet, they required the
longest hospitalisation times, which is presumably associated to the presence of comorbidities
and other age-related complications [26].
Finally, an assessment of direct medical costs was performed. Mean cost per patient was
€10,992 during the study period, with a decreasing tendency observed over time. Yet, the
marked reduction measured the year 2016 could be related to the shift to ICD-10 coding. Fur-
ther research will be required to determine whether this decrease can be associated to the
introduction of screening programmes and the earlier detection of this cancer type [27]. As a
reference, the public healthcare cost per person in Spain was approximately €1,600 the year
2017, with 63.2% of total costs dedicated to specialised care [28]. The costs measured herein
are likely to be derived from surgical procedures, which were estimated to account for up to
59.2% of all costs of colorectal cancer patients in one Spanish hospital [29].
In the same way, differences in costs between cancer types and stages, patients age and
comorbidity status have been documented in several occasions and should be taken into
account in future studies for the optimisation of healthcare protocols [30, 31].
A number of limitations may have influence in the results obtained. ICD-9-CM and ICD-
10-CM codes did not allow differentiation between the distinct stages of colorectal cancer, pre-
venting further analyses; in addition, the introduction of ICD-10 codification the year 2016
represented a source of error due to the gradual implementation of this codification.
Conclusions
The implementation of colorectal cancer screening programmes in Spain presumably pro-
voked the decrease in the number of new diagnoses in patients aged 75 to 79 years; however,
in-hospital mortality remained stable. Such programmes should be promoted to achieve
higher participation rates in an effort to reduce incidence and the number of patients present-
ing metastasis at first admission. The roles of anaemia and overweight in colorectal cancer
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